Whitehawk Therapeutics (WHWK) Free Cash Flow (2010 - 2026)
Whitehawk Therapeutics (WHWK) reported Free Cash Flow of -$22.2 million for Q1 2026, down 78.88% year-over-year from -$105.2 million in Q1 2025, and down 24.86% quarter-over-quarter from -$17.8 million in Q4 2025.
Whitehawk Therapeutics (WHWK) Free Cash Flow (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 17 years of Free Cash Flow data on file, last reported at -$22.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$22.2 million, down 78.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$107.8 million (down 104.41% YoY), and the FY2025 annual result was -$98.0 million, down 61.42% from the prior year.
- Free Cash Flow eased to -$22.2 million in Q1 2026 per WHWK's latest filing, from -$17.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$8.5 million in Q3 2022 and troughed at -$52.4 million in Q2 2025.
- A 5-year average of -$17.3 million and a median of -$15.4 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 51.12% in 2024, then slumped 481.71% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$11.4 million in 2022, then declined by 18.49% to -$13.5 million in 2023, then dropped by 9.22% to -$14.7 million in 2024, then fell by 20.68% to -$17.8 million in 2025, then retreated by 24.86% to -$22.2 million in 2026.
- Business Quant data shows WHWK's Free Cash Flow at -$22.2 million in Q1 2026, -$17.8 million in Q4 2025, and -$15.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | -22.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.21 Mn |
| Mar 31, 2026 | -22.21 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -52.41 Mn |
| Jun 30, 2025 | -52.41 Mn |
| Mar 31, 2025 | -12.42 Mn |
| Mar 31, 2025 | -12.42 Mn |
| Dec 31, 2024 | -14.74 Mn |
| Dec 31, 2024 | -14.74 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Sep 30, 2024 | -16.56 Mn |
| Jun 30, 2024 | -9.01 Mn |
| Jun 30, 2024 | -9.01 Mn |
| Mar 31, 2024 | -20.39 Mn |
| Mar 31, 2024 | -20.39 Mn |
| Dec 31, 2023 | -13.49 Mn |
| Dec 31, 2023 | -13.49 Mn |